Vanguard Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $392M | Sell |
2,073,892
-2,391
| -0.1% | -$459K | 0.01% | 1200 |
|
|
2025
Q3 | $368M | Sell |
2,076,283
-13,088
| -0.6% | -$1.95M | 0.01% | 1228 |
|
|
2025
Q2 | $238M | Buy |
2,089,371
+33,639
| +2% | +$3.6M | ﹤0.01% | 1430 |
|
|
2025
Q1 | $216M | Sell |
2,055,732
-29,895
| -1% | -$3.38M | ﹤0.01% | 1448 |
|
|
2024
Q4 | $223M | Buy |
2,085,627
+115,005
| +6% | +$13M | ﹤0.01% | 1493 |
|
|
2024
Q3 | $197M | Buy |
1,970,622
+43,748
| +2% | +$4.4M | ﹤0.01% | 1550 |
|
|
2024
Q2 | $162M | Buy |
1,926,874
+42,762
| +2% | +$3.4M | ﹤0.01% | 1606 |
|
|
2024
Q1 | $138M | Buy |
1,884,112
+7,598
| +0.4% | +$560K | ﹤0.01% | 1701 |
|
|
2023
Q4 | $134M | Buy |
1,876,514
+24,653
| +1% | +$1.45M | ﹤0.01% | 1707 |
|
|
2023
Q3 | $111M | Sell |
1,851,861
-1,492
| -0.1% | -$98.2K | ﹤0.01% | 1750 |
|
|
2023
Q2 | $134M | Sell |
1,853,353
-5,261
| -0.3% | -$395K | ﹤0.01% | 1689 |
|
|
2023
Q1 | $137M | Buy |
1,858,614
+15,499
| +0.8% | +$1.1M | ﹤0.01% | 1657 |
|
|
2022
Q4 | $123M | Sell |
1,843,115
-1,031,728
| -36% | -$67.1M | ﹤0.01% | 1695 |
|
|
2022
Q3 | $154M | Buy |
2,874,843
+31,163
| +1% | +$1.83M | ﹤0.01% | 1540 |
|
|
2022
Q2 | $158M | Buy |
2,843,680
+74,276
| +3% | +$4.21M | ﹤0.01% | 1564 |
|
|
2022
Q1 | $194M | Buy |
2,769,404
+17,478
| +0.6% | +$1.27M | ﹤0.01% | 1573 |
|
|
2021
Q4 | $265M | Sell |
2,751,926
-8,906
| -0.3% | -$823K | 0.01% | 1432 |
|
|
2021
Q3 | $240M | Buy |
2,760,832
+317,612
| +13% | +$24.6M | 0.01% | 1493 |
|
|
2021
Q2 | $200M | Buy |
2,443,220
+9,478
| +0.4% | +$788K | 0.01% | 1632 |
|
|
2021
Q1 | $231M | Buy |
2,433,742
+95,085
| +4% | +$8.99M | 0.01% | 1509 |
|
|
2020
Q4 | $145M | Buy |
2,338,657
+47,500
| +2% | +$2.71M | ﹤0.01% | 1646 |
|
|
2020
Q3 | $136M | Sell |
2,291,157
-91,868
| -4% | -$6.27M | ﹤0.01% | 1513 |
|
|
2020
Q2 | $166M | Sell |
2,383,025
-172,077
| -7% | -$10.9M | 0.01% | 1395 |
|
|
2020
Q1 | $116M | Buy |
2,555,102
+38,371
| +2% | +$2.17M | ﹤0.01% | 1446 |
|
|
2019
Q4 | $164M | Sell |
2,516,731
-115,494
| -4% | -$7.72M | 0.01% | 1494 |
|
|
2019
Q3 | $163M | Sell |
2,632,225
-110,542
| -4% | -$6.94M | 0.01% | 1456 |
|
|
2019
Q2 | $195M | Sell |
2,742,767
-354,543
| -11% | -$26.1M | 0.01% | 1375 |
|
|
2019
Q1 | $243M | Buy |
3,097,310
+3,760
| +0.1% | +$285K | 0.01% | 1224 |
|
|
2018
Q4 | $262M | Sell |
3,093,550
-256,940
| -8% | -$27.4M | 0.01% | 1072 |
|
|
2018
Q3 | $574M | Buy |
3,350,490
+107,063
| +3% | +$16.1M | 0.02% | 721 |
|
|
2018
Q2 | $419M | Buy |
3,243,427
+130,815
| +4% | +$14.6M | 0.02% | 868 |
|
|
2018
Q1 | $321M | Buy |
3,112,612
+150,566
| +5% | +$14.9M | 0.01% | 989 |
|
|
2017
Q4 | $253M | Buy |
2,962,046
+120,603
| +4% | +$10.5M | 0.01% | 1139 |
|
|
2017
Q3 | $241M | Buy |
2,841,443
+49,309
| +2% | +$3.9M | 0.01% | 1129 |
|
|
2017
Q2 | $211M | Buy |
2,792,134
+86,882
| +3% | +$6.08M | 0.01% | 1196 |
|
|
2017
Q1 | $179M | Buy |
2,705,252
+118,932
| +5% | +$7.82M | 0.01% | 1295 |
|
|
2016
Q4 | $164M | Buy |
2,586,320
+86,698
| +3% | +$5.47M | 0.01% | 1303 |
|
|
2016
Q3 | $159M | Buy |
2,499,622
+69,772
| +3% | +$5.12M | 0.01% | 1264 |
|
|
2016
Q2 | $181M | Buy |
2,429,850
+179,227
| +8% | +$13.3M | 0.01% | 1111 |
|
|
2016
Q1 | $150M | Buy |
2,250,623
+89,053
| +4% | +$5.41M | 0.01% | 1189 |
|
|
2015
Q4 | $146M | Buy |
2,161,570
+24,744
| +1% | +$1.53M | 0.01% | 1206 |
|
|
2015
Q3 | $114M | Buy |
2,136,826
+34,070
| +2% | +$2.07M | 0.01% | 1342 |
|
|
2015
Q2 | $132M | Buy |
2,102,756
+472,712
| +29% | +$25.8M | 0.01% | 1346 |
|
|
2015
Q1 | $78.4M | Buy |
1,630,044
+31,446
| +2% | +$1.2M | 0.01% | 1670 |
|
|
2014
Q4 | $53.1M | Buy |
1,598,598
+123,838
| +8% | +$4.03M | ﹤0.01% | 1801 |
|
|
2014
Q3 | $43.2M | Sell |
1,474,760
-198,423
| -12% | -$6.59M | ﹤0.01% | 1880 |
|
|
2014
Q2 | $65M | Buy |
1,673,183
+95,448
| +6% | +$3.87M | 0.01% | 1695 |
|
|
2014
Q1 | $66.2M | Buy |
1,577,735
+487,668
| +45% | +$20.3M | 0.01% | 1638 |
|
|
2013
Q4 | $35.8M | Buy |
1,090,067
+204,235
| +23% | +$6.65M | ﹤0.01% | 1943 |
|
|
2013
Q3 | $23.9M | Buy |
885,832
+15,267
| +2% | +$430K | ﹤0.01% | 2047 |
|
|
2013
Q2 | $20.3M | Buy |
+870,565
| New | +$15.7M | ﹤0.01% | 2063 |
|
Other funds holding LGND
NAMI
CC
SIMG
Vanguard Group's LGND Position: Q4 2025 in Review
Vanguard Group reduced its Ligand Pharmaceuticals (LGND) stake by 0.12% in Q4 2025, selling an estimated $459K and leaving 2,073,892 shares worth $392M. The position accounts for 0.01% of the portfolio, ranked #1200.
Vanguard Group first reported a position in LGND in Q2 2013 and has held it in 51 quarters since. The position peaked at $574M in Q3 2018. 349 funds tracked by Wall St. Rank hold LGND as of Q4 2025.
- Vanguard Group held 2,073,892 shares of Ligand Pharmaceuticals worth $392M as of Q4 2025.
- Vanguard Group sold 2,391 Ligand Pharmaceuticals shares in Q4 2025, an estimated $459K.
- Ligand Pharmaceuticals made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #1200 holding.
- Vanguard Group first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Vanguard Group's Ligand Pharmaceuticals position peaked at $574M in Q3 2018.
- 349 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.